Physician profile
Chris R Farnum
NPI 1770581621
$102,173.65
in general payments reported to CMS, 2019-2025
41 companies · $30K in 2025
The $30K reported for 2025 was more than what 97% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $8,331 · 2021: $3,094 · 2022: $5,726 · 2023: $11K · 2024: $28K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Travel and Lodging: $5,505 · Food and Beverage: $4,662 · Education: $20.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,500.00 |
| Travel and Lodging | $5,505.49 |
| Food and Beverage | $4,662.35 |
| Education | $20.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $73,754.07 | 2021-2025 | |
| Allergan, INC. | $12,760.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $10,936.86 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Gilead Sciences, INC. | $1,129.84 | 2019-2024 | Veklury, Ambisome |
| Paratek Pharmaceuticals, INC. | $596.18 | 2022-2025 | Nuzyra |
| Insmed, INC. | $501.07 | 2019-2022 | |
| Glaxosmithkline, LLC. | $473.84 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Melinta Therapeutics, LLC | $223.87 | 2023-2024 | Rezzayo, Kimyrsa, Vabomere |
| Amgen INC. | $161.83 | 2021-2025 | Otezla, Repatha |
| Ferring Pharmaceuticals INC. | $120.25 | 2023 | Rebyota |
| Biohaven Pharmaceutical Holding Company Ltd. | $120.12 | 2022 | |
| Novo Nordisk INC | $108.38 | 2020-2024 | Rybelsus, Ozempic |
| Viiv Healthcare Company | $107.30 | 2023-2024 | Cabenuva, Apretude, Dovato |
| Otsuka America Pharmaceutical, INC. | $105.76 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $103.70 | 2025 | Auvelity, Symbravo |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Farnum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.